Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The combination of target drugs Tafinlar-Mekinist is approved for nearly any type of advanced solid tumor that has the BRAF gene mutation.
A combo treatment of Tafinlar and Mekinist may be better than chemo for some children with a brain cancer called low-grade glioma.
Combination therapy using Taflinar and Mekinst led to improved response for pediatric patients with low-grade gliomas
Three independent studies suggest a way to thwart a mutated gene that drives tumor growth in 95 percent of people with the disease.
Tafinlar plus Mekinist shrank tumors in people with biliary tract cancer and adenocarcinoma of the small intestine.
Tafinlar and Mekinist approved for a third cancer with specific gene mutation.
People who received the combination treatment had a statistically significant improvement in relapse-free survival.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.